Ophthalmic ropinirole is an equally effective emetic agent in healthy dogs compared to intravenous apomorphine.

IF 2.6 2区农林科学 Q1 VETERINARY SCIENCES

Frontiers in Veterinary Science Pub Date : 2025-03-17 eCollection Date: 2025-01-01 DOI:10.3389/fvets.2025.1554107

Jack A Lee, Katie Como, Xiaojuan Zhu, Julie Schildt

{"title":"Ophthalmic ropinirole is an equally effective emetic agent in healthy dogs compared to intravenous apomorphine.","authors":"Jack A Lee, Katie Como, Xiaojuan Zhu, Julie Schildt","doi":"10.3389/fvets.2025.1554107","DOIUrl":null,"url":null,"abstract":"Introduction: Emesis is commonly induced in the veterinary setting due to toxin or foreign material ingestion. The dopamine agonist apomorphine is commonly used for this indication. The novel dopamine-2 specific agonist ropinirole was approved by the U.S. Food and Drug Administration for this indication in 2020. Data to compare the efficacy and adverse effects profile of these medications is important for clinical decision making.Methods: This blinded randomized crossover trial compared the efficacy of intravenous apomorphine to ophthalmic ropinirole in 24 healthy dogs. Factors assessed include efficacy at inducing vomiting within 20 min, need for redosing of the emetic agent, time to start of emesis, and incidence of adverse effects.Results: Both apomorphine and ropinirole were highly effective at emesis induction, with 95.8 and 100% success rates, respectively, and no difference between groups. Repeated dosing was needed after 20 min in 25% of the apomorphine group and 8.3% of the ropinirole group for successful emesis induction. Median time to onset was significantly shorter with apomorphine (1.18 min) than ropinirole (8.85 min). Incidence of adverse effects was similar, with a higher incidence of ocular redness and protracted vomiting in the ropinirole group.Conclusion: These results suggest similar efficacy of ropinirole compared to apomorphine, with similar adverse effect rates.","PeriodicalId":12772,"journal":{"name":"Frontiers in Veterinary Science","volume":"12 ","pages":"1554107"},"PeriodicalIF":2.6000,"publicationDate":"2025-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11955828/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Veterinary Science","FirstCategoryId":"97","ListUrlMain":"https://doi.org/10.3389/fvets.2025.1554107","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"VETERINARY SCIENCES","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Emesis is commonly induced in the veterinary setting due to toxin or foreign material ingestion. The dopamine agonist apomorphine is commonly used for this indication. The novel dopamine-2 specific agonist ropinirole was approved by the U.S. Food and Drug Administration for this indication in 2020. Data to compare the efficacy and adverse effects profile of these medications is important for clinical decision making.

Methods: This blinded randomized crossover trial compared the efficacy of intravenous apomorphine to ophthalmic ropinirole in 24 healthy dogs. Factors assessed include efficacy at inducing vomiting within 20 min, need for redosing of the emetic agent, time to start of emesis, and incidence of adverse effects.

Results: Both apomorphine and ropinirole were highly effective at emesis induction, with 95.8 and 100% success rates, respectively, and no difference between groups. Repeated dosing was needed after 20 min in 25% of the apomorphine group and 8.3% of the ropinirole group for successful emesis induction. Median time to onset was significantly shorter with apomorphine (1.18 min) than ropinirole (8.85 min). Incidence of adverse effects was similar, with a higher incidence of ocular redness and protracted vomiting in the ropinirole group.

Conclusion: These results suggest similar efficacy of ropinirole compared to apomorphine, with similar adverse effect rates.

查看原文本刊更多论文

眼用罗匹尼罗是一种同样有效的催吐剂在健康的狗相比，静脉注射阿波啡。

导读：在兽医环境中，呕吐通常是由于毒素或异物摄入引起的。多巴胺激动剂阿波啡常用于此适应症。新型多巴胺-2特异性激动剂罗匹尼罗于2020年被美国食品和药物管理局批准用于该适应症。比较这些药物的疗效和不良反应的数据对临床决策很重要。方法：对24只健康犬进行盲法随机交叉试验，比较静脉注射阿波啡与眼用罗匹尼罗的疗效。评估的因素包括20分钟内诱导呕吐的效果、是否需要重新给药、开始呕吐的时间和不良反应的发生率。结果：阿波吗啡和罗匹尼罗诱导呕吐效果良好，成功率分别为95.8和100%，两组间差异无统计学意义。25%的阿波啡组和8.3%的罗匹尼罗组在20分钟后需要重复给药才能成功诱导呕吐。阿波啡组的中位发病时间（1.18 min）明显短于罗匹尼罗组（8.85 min）。不良反应的发生率相似，在罗匹尼罗组中，眼部红肿和持续性呕吐的发生率较高。结论：罗匹尼罗与阿波啡疗效相近，不良反应发生率相近。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Frontiers in Veterinary Science Veterinary-General Veterinary

CiteScore

4.80

自引率

9.40%

发文量

1870

审稿时长

14 weeks

期刊介绍： Frontiers in Veterinary Science is a global, peer-reviewed, Open Access journal that bridges animal and human health, brings a comparative approach to medical and surgical challenges, and advances innovative biotechnology and therapy. Veterinary research today is interdisciplinary, collaborative, and socially relevant, transforming how we understand and investigate animal health and disease. Fundamental research in emerging infectious diseases, predictive genomics, stem cell therapy, and translational modelling is grounded within the integrative social context of public and environmental health, wildlife conservation, novel biomarkers, societal well-being, and cutting-edge clinical practice and specialization. Frontiers in Veterinary Science brings a 21st-century approach—networked, collaborative, and Open Access—to communicate this progress and innovation to both the specialist and to the wider audience of readers in the field. Frontiers in Veterinary Science publishes articles on outstanding discoveries across a wide spectrum of translational, foundational, and clinical research. The journal''s mission is to bring all relevant veterinary sciences together on a single platform with the goal of improving animal and human health.